<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00374998</url>
  </required_header>
  <id_info>
    <org_study_id>VAC027.1</org_study_id>
    <secondary_id>EudraCT number: 2004-002424-17</secondary_id>
    <secondary_id>EMVI trial identifier: PP_1_04</secondary_id>
    <nct_id>NCT00374998</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity Study of the Malaria Vaccines FP9 PP and MVA PP</brief_title>
  <official_title>A Phase I Study to Assess the Safety and Immunogenicity of the Polyprotein Malaria Vaccine Candidates FP9 PP and MVA PP in Healthy Adults Using a Prime-Boost Delivery Schedule</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Malaria Vaccine Initiative</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wellcome Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>European Malaria Vaccine Initiative</source>
  <brief_summary>
    <textblock>
      This study examines two new malaria vaccines (FP9-PP and MVA-PP) in healthy human volunteers&#xD;
      to determine their safety and ability to induce a measurable immune response against malaria.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Malaria infection kills over 2 million people each year. It is a major problem for those who&#xD;
      live in endemic areas and for travellers. There is clearly a great need for a safe effective&#xD;
      malaria vaccine.&#xD;
&#xD;
      The purpose of this study is to test two candidate malaria vaccines (FP9-PP and MVA-PP) in&#xD;
      different concentrations and combinations. These live viral vectors encode a 'polyprotein' of&#xD;
      six fused malaria antigens expressed at liver and blood stages of the malaria parasite&#xD;
      lifecycle. MVA-PP uses the Modified Virus Ankara vector, a weakened form of the smallpox&#xD;
      vaccine, vaccinia. FP9-PP uses a highly attenuated avian pox virus (FP9) as the vector&#xD;
      instead. The two vaccines will be used in combination in a 'prime boost' strategy to enhance&#xD;
      the response of the cellular immune system.&#xD;
&#xD;
      This study will:&#xD;
&#xD;
        1. Examine safety&#xD;
&#xD;
        2. Examine immunogenicity&#xD;
&#xD;
        3. Provide a subgroup of vaccinated volunteers to test clinical efficacy in the following&#xD;
           malaria challenge study (VAC027.2)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date>January 2007</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immediate reactogenicity</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events occurring before the end of the trial</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Biological safety (haematological and biochemical indices)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>T-cell immunogenicity (prime-boost groups)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Humoral immunogenicity (prime-boost groups)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gene expression (prime-boost groups)</measure>
  </secondary_outcome>
  <enrollment>35</enrollment>
  <condition>Malaria, Falciparum</condition>
  <condition>Malaria</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>FP9-PP (FP9 polyprotein)</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MVA-PP (Modified Virus Ankara polyprotein)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy adults aged 18 to 50 years&#xD;
&#xD;
          -  Resident in or near Oxford, UK for the duration of the vaccination study&#xD;
&#xD;
          -  Willingness to allow the investigators to access hospital and General Practitioner&#xD;
             medical notes&#xD;
&#xD;
          -  For females only, willingness to practice continuous effective contraception during&#xD;
             the study and if participating, during the subsequent challenge study.&#xD;
&#xD;
          -  Agreement to refrain from blood donation during the course of the study&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Willingness to undergo an HIV test&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any deviation from the protocol-defined normal range in biochemistry or haematology&#xD;
             blood tests or in urine analysis&#xD;
&#xD;
          -  Prior receipt of an investigational malaria vaccine&#xD;
&#xD;
          -  Use of any investigational or non-registered drug, vaccine or medical device other&#xD;
             than the study vaccine within 30 days preceding dosing of study vaccine, or planned&#xD;
             use during the study period&#xD;
&#xD;
          -  Administration of chronic immunosuppressive drugs or other immune modifying drugs&#xD;
             within six months of vaccination&#xD;
&#xD;
          -  History of malaria chemoprophylaxis with chloroquine within 5 months prior to the&#xD;
             planned challenge, with Lariam within 6 weeks prior to the challenge, and Riamet&#xD;
             within 2 weeks prior to the challenge&#xD;
&#xD;
          -  Any history of malaria&#xD;
&#xD;
          -  Travel to a malaria endemic country within the previous 6 months prior to the planned&#xD;
             challenge&#xD;
&#xD;
          -  Planned travel to malarious areas during the study period&#xD;
&#xD;
          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, including&#xD;
             human immunodeficiency virus (HIV) infection and asplenia&#xD;
&#xD;
          -  History of allergic disease or reactions likely to be exacerbated by any component of&#xD;
             the vaccine, e.g. egg products&#xD;
&#xD;
          -  Evidence of cardiovascular disease&#xD;
&#xD;
          -  History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in&#xD;
             situ)&#xD;
&#xD;
          -  History of haemoglobinopathies&#xD;
&#xD;
          -  History of diabetes mellitus&#xD;
&#xD;
          -  Chronic or active neurological disease&#xD;
&#xD;
          -  Chronic gastrointestinal disease&#xD;
&#xD;
          -  History of more than 2 hospitalisations for invasive bacterial infections&#xD;
&#xD;
          -  Suspected or known current alcohol abuse as defined by an alcohol intake of greater&#xD;
             than 42 units every week&#xD;
&#xD;
          -  Seropositive for hepatitis B surface antigen (HBsAg)&#xD;
&#xD;
          -  Seropositive for hepatitis C virus (antibodies to HCV)&#xD;
&#xD;
          -  Hepatomegaly, right upper quadrant abdominal pain or tenderness&#xD;
&#xD;
          -  Evidence of serious psychiatric condition&#xD;
&#xD;
          -  Any other on-going chronic illness requiring hospital specialist supervision&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adrian VS Hill, MA, BM BCh, DPhil, DM</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oxford</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre for Clinical Vaccinology &amp; Tropical Medicine, University of Oxford</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2007</verification_date>
  <study_first_submitted>September 10, 2006</study_first_submitted>
  <study_first_submitted_qc>September 10, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2006</study_first_posted>
  <last_update_submitted>February 28, 2007</last_update_submitted>
  <last_update_submitted_qc>February 28, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 1, 2007</last_update_posted>
  <keyword>Malaria</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Prime-boost</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
    <mesh_term>Malaria, Falciparum</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

